Exploiting ROS and metabolic differences to kill cisplatin resistant lung cancer.

Saved in:
Bibliographic Details
Title: Exploiting ROS and metabolic differences to kill cisplatin resistant lung cancer.
Authors: Wangpaichitr M; Miami VA Healthcare System, Research Service, Miami, FL, USA.; Department of Surgery, Cardiothoracic Surgery, University of Miami, Miami, FL, USA., Wu C; Miami VA Healthcare System, Research Service, Miami, FL, USA., Li YY; Department of Medicine, Hematology/Oncology, University of Miami, Miami, FL, USA., Nguyen DJM; Department of Biology, University of Miami, Miami, FL, USA., Kandemir H; School of Medicine, Koc University, Istanbul, Turkey., Shah S; Department of Biology, University of Miami, Miami, FL, USA., Chen S; Department of Neurosurgery, Taipei Medical University-Wan Fang Hospital, Taipei, Taiwan., Feun LG; Department of Medicine, Hematology/Oncology, University of Miami, Miami, FL, USA., Prince JS; Department of Biology, University of Miami, Miami, FL, USA., Kuo MT; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Savaraj N; Miami VA Healthcare System, Research Service, Miami, FL, USA.; Department of Medicine, Hematology/Oncology, University of Miami, Miami, FL, USA.
Source: Oncotarget [Oncotarget] 2017 Jul 25; Vol. 8 (30), pp. 49275-49292.
Publication Type: Journal Article
Journal Info: Publisher: Impact Journals Country of Publication: United States NLM ID: 101532965 Publication Model: Print Cited Medium: Internet ISSN: 1949-2553 (Electronic) Linking ISSN: 19492553 NLM ISO Abbreviation: Oncotarget Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1949-2553
DOI:10.18632/oncotarget.17568